Amgen Sets New Timetable for Completion of Irish Manufacturing Facility
Thousand Oaks, CA (Apr. 3)-Amgen, Inc. has provided a new schedule for the completion of a new manufacturing facility in County Cork, Ireland.
Thousand Oaks, CA (Apr. 3)-Amgen, Inc. (www.amgen.com) has provided a new schedule for the completion of a new manufacturing facility in County Cork, Ireland.
In 2006, Amgen announced plans to invest more than $1 billion in new process development, bulk protein production, and fill-and-finish facilities, with an initial target of beginning operations in the 2010 timeframe.
An Amgen official explained the company has outlined a revised schedule for starting operations based on a recently conducted periodic review of its manufacturing facilities.
The bulk manufacturing capacity is scheduled to be operational in 2012, with regulatory licensure of the facility anticipated for 2013. The process development laboratories will be constructed in conjunction with the bulk facility or as needed to support start-up of the manufacturing capacity. The fill-and-finish capacity is scheduled to be operational by 2013, with regulatory licensure anticipated by 2014.
Once fully operational, the site is expected to staff 1,100.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
